Nature Medicine | Spoonful of Medicine

PrEP trial successes prompt cost-effectiveness questions

By Roxanne Khamsi Clinical trial data are starting to pour in demonstrating that the HIV prevention strategy known as ‘pre-exposure prophylaxis’ is an effective way of keeping people at high risk of infection disease free. In July, researchers reported at the International AIDS Society Conference in Rome that taking an antiretroviral drug called Truvada offered a 73% protection rate for heterosexual couples in East Africa in which only one person had HIV. At the same meeting, the US Centers for Disease Control and Prevention also announced trial results demonstrating a 63% reduction in transmission among young adults in Botswana taking 

BACK TO ARTICLE

Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.

BACK TO ARTICLE